Simpson Thacher Adds Prominent Real Estate Finance Partner
13.5.2022 08:00:00 EEST | Business Wire | Press release
Simpson Thacher & Bartlett LLP today announced that James Esterkin will rejoin the Real Estate Practice as a Partner in the Firm’s London office.
James advises private equity sponsors and other investors in connection with the financing of U.K. and European real estate and related assets. He specializes in complex real estate acquisition and development financing, non-performing loan financing arrangements and the restructuring of real estate-related secured debt.
“We are very pleased to welcome James back to our team in London,” said Alden Millard, Chair of Simpson Thacher’s Executive Committee. “James has a unique blend of skills across the real estate sector with experience in all sub-real estate asset classes and European geographies that will be of tremendous value to our clients.”
For nearly 45 years, Simpson Thacher’s London office has advised clients on a wide range of transactions and legal matters throughout Europe. With approximately 185 attorneys, the office offers a team of English and U.S.-trained lawyers advising clients on a broad array of corporate transactions and legal disputes. The Firm’s London Real Estate Practice regularly advises on some of the largest and most complex matters throughout Europe. Recent work includes representing Blackstone Real Estate Partners in connection with nearly all of their financings in the region, across more than 20 jurisdictions and all real estate subsectors, as well as other real estate sponsors, including KKR and Apollo, on almost all of their European sponsor-side real estate finance work. Among its many highlights, the Firm recently advised Blackstone on its €21 billion recapitalization of Mileway—the largest-ever private real estate transaction.
“James will be an excellent addition to our team,” said Tom Lloyd, who leads the Firm’s Real Estate Finance team in the London office. “His extensive experience advising private equity sponsors for almost his entire career will enhance the offerings of our growing real estate finance practice.”
London office Managing Partner Jason Glover noted, “James has established himself as a prominent advisor to an impressive roster of real estate sponsors. He is an exceptional match for our real estate finance capabilities in London.”
“Simpson Thacher is renowned for providing outstanding, innovative advice to the world’s most sophisticated sponsors in the real estate sector,” said James. “I’m thrilled to be returning to the Firm and am excited to further push forward the growth of the Real Estate Finance team in London.”
James was previously a Partner in the London office of Kirkland & Ellis LLP, beginning in 2017. Prior to that, he worked on Simpson Thacher’s London Real Estate team as an Associate from 2013 to 2017. He received his LPC, with distinction, and an LL.M. in International Legal Practice from University of Law, London, and his LL.B. in Law from University of Nottingham. James received a Master of Science in Real Estate Development from University of Westminster.
ABOUT SIMPSON THACHER
Simpson Thacher & Bartlett LLP (www.simpsonthacher.com) is one of the world’s leading international law firms. The Firm was established in 1884 and has more than 1,000 lawyers. Headquartered in New York with offices in Beijing, Brussels, Hong Kong, Houston, London, Los Angeles, Palo Alto, São Paulo, Tokyo and Washington, D.C., the Firm provides coordinated legal advice and transactional capability to clients around the globe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006086/en/
Contact information
Caroline Fatchett
Assoc. Director, Communications
mediainquiries@stblaw.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom